Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9031766 | 0.80 | METAP1 (0.33) | METAP1 | |
| SCHEMBL23084155 | 0.79 | METAP1 (0.53) | METAP1 | |
| SCHEMBL4489302 | 0.77 | EPHX2 (0.40) | METAP1 | |
| SCHEMBL12281999 | 0.76 | METAP1 (0.46) | METAP1 | |
| SCHEMBL25479775 | 0.74 | KDM4E (0.45) | METAP1 | |
| SCHEMBL6927937 | 0.74 | HTT (0.32) | — | |
| SCHEMBL3831460 | 0.73 | MTNR1A (0.35) | — | |
| SCHEMBL22214065 | 0.72 | KCNH2 (0.52) | METAP1 | |
| SCHEMBL9031402 | 0.72 | HRH3 (0.34) | — | |
| SCHEMBL25480440 | 0.71 | METAP1 (0.42) | METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541477-B2 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050222161-A1 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222161-A1 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | MC1R, MCHR1, MCHR2 | METAP1 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.